Home
Resources
Follow portfolio news
...

WuXi Biologics sells its vaccine plant in Ireland to Merck for 500 million euros

Published on
23/1/2025
Amended on
23/3/2026
0
minute(s)
Odyssey 2021
WuXi Biologics
WuXi Biologics, world leader in biopharmaceutical outsourcing, confirms its strategic agility with the sale of its vaccine plant in Dundalk, Ireland, to Merck & Co. for 500 million euros. This state-of-the-art facility, to be built in 2019, testifies to WuXi's technological excellence and its ability to meet the needs of international pharmaceutical giants.
By
Charles Pinsolle
Charles Pinsolle
WuXi Biologics sells its vaccine plant in Ireland to Merck for 500 million euros
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

A strategic transaction that strengthens WuXi's global impact

Despite a demanding market context, marked by regulatory changes and geopolitical challenges, WuXi Biologics, the company featured in the Vintage Altaroc Odyssey 2021, continues to demonstrate its resilience and sense of innovation. The Dundalk plant, the result of an initial investment of 200 million euros, was a model of integrated production for vaccines. The decision to sell this site to Merck stems from a clear vision: to refocus its efforts on strategic, high value-added projects and maximize the overall impact of its activities.

Merck, which already operated the site via a 20-year contract to manufacture vaccines generating $150 million in annual revenues, was the natural partner for this acquisition. This transaction illustrates not only the quality of WuXi's infrastructure and expertise, but also its ability to collaborate with major industry players.

WuXi Biologics: a forward-looking trajectory

The sale of the Dundalk site is part of WuXi Biologics' proactive strategy to optimize its resources in response to market developments and emerging opportunities. With ongoing investment in innovation and a strong portfolio of assets, the company continues to reinforce its position as a world leader in biologics manufacturing.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
Europe
No items found.
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.